No Data
What's Going On With Huamacyte Shares Tuesday?
Humacyte, Inc. (NASDAQ:HUMA) stock is trending on Tuesday. In July, the company has so far added Dr. John P. Bamforth and Dr. Keith Anthony to its Board of Directors, entered a license agreement
Press Release: Humacyte Board of Directors Strengthened With Addition of John P. Bamforth and Keith Anthony Jones
Humacyte Board of Directors Strengthened with Addition of John P. Bamforth and Keith Anthony Jones DURHAM, N.C., July 16, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage
Humacyte Board of Directors Strengthened With Addition of John P. Bamforth and Keith Anthony Jones
PDF VersionDURHAM, N.C., July 16, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human
Humacyte Is Maintained at Buy by BTIG
Humacyte Is Maintained at Buy by
Humacyte Price Target Raised to $11.00/Share From $8.00 by BTIG
Humacyte Price Target Raised to $11.00/Share From $8.00 by
MicroStrategy, Coinbase, Robinhood, Tesla And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Dow Jones index gaining around 250 points on Monday.Shares of MicroStrategy Incorporated (NASDAQ:MSTR) rose sharply during Monday's session amid a rise Bitcoin.